Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CTBP2P4 is classified as a pseudogene of the C-terminal binding protein 2 (CTBP2) gene. Pseudogenes are genomic sequences similar to normal genes but are typically non-functional due to mutations that prevent them from coding for proteins. CTBP2P4 does not produce a functional protein, is not considered a therapeutic target, and is generally not involved in biological processes or disease pathology. It is distinct from the functional CTBP2 gene, which encodes a transcriptional corepressor implicated in development and multiple cancers, but those functions do not apply to CTBP2P4[5]. According to current databases and genetic resources, CTBP2P4 should not be considered a target for therapeutic intervention or research focused on protein function, and any references to targeting CTBP2P4 for drug development or biomarker research would be incorrect[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on C-terminal binding protein 2 pseudogene 4 (CTBP2P4).